|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
TUBB3, ERCC1 and P-gp are involved in the occurrence and development of ovarian cancer and can be used as important indexes judging the severity of ovarian cancer, providing a reference for the occurrence and development of the disease in ovarian cancer patients in clinical practice.
|
30570863 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results indicated that <i>ERCC1, XPC</i> and <i>ERCC2</i> might influence ovarian cancer susceptibility.
|
29669843 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, we suggest that ERCC1+CTCs could additionally be useful as a surrogate for monitoring platinum-based chemotherapy and to assess the post-therapeutic outcome of ovarian cancer.
|
28388557 |
2017 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.
|
28623887 |
2017 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer.
|
29156754 |
2017 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The allelic frequencies of the UGT1A1 and ERCC1 variants in a group of 89 patients with advanced ovarian cancer were determined.
|
26125934 |
2015 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, ERCC1 could be a potential therapeutic target for the therapy of cisplatin-resistant ovarian cancer and it would provide new ideas for epigenetic therapy of drug-resistant epithelial ovarian cancer.
|
25941922 |
2015 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of ERCC1(+)CTC can serve as a blood-based diagnostic biomarker for predicting platinum resistance at primary diagnosis of ovarian cancer.
|
25015375 |
2014 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our firstly investigation of links between polymorphisms in the ERCC1 gene and the risk of ovarian cancer in Chinese population demonstrated no significant association.
|
22901125 |
2012 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In resistance group of serous ovarian cancer, ERCC1 and XPD protein expression levels were significantly higher than those of sensitivity group, and after receiving neoadjuvant chemotherapy, they showed 23% and 32% higher than before.
|
18081788 |
2009 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, this study shows that low BRCA1 and ERCC1 expression correlate with improved survival in advanced OC and HDAC inhibition induces synergistic cytotoxicity with platinum in vitro.
|
19035454 |
2009 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
LHGDN |
In summary, this study shows that low BRCA1 and ERCC1 expression correlate with improved survival in advanced OC and HDAC inhibition induces synergistic cytotoxicity with platinum in vitro.
|
19035454 |
2009 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
|
18640939 |
2008 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One of the mechanisms of resistance of ovarian tumours to cisplatin is increased nucleotide excision repair activity, in particular increased levels of the endonuclease ERCC1.
|
15688021 |
2005 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, overexpression of ERCC1 and other NER enzymes during ovarian cancer chemotherapy with cisplatin appears to be implicated in the formation of cellular and clinical drug resistance.
|
12915808 |
2003 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia.
|
12867068 |
2003 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia.
|
14668933 |
2003 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
|
11936875 |
2001 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied the DNA sequence of the entire coding region of ERCC1 gene, in five cell lines established from human ovarian cancer (A2780, A2780/CP70, MCAS, OVCAR-3, SK-OV-3), 29 human ovarian cancer tumor tissue specimens, one human T-lymphocyte cell line (H9), and non-malignant human ovary tissue (NHO).
|
9360634 |
1997 |